索磷布韦-维帕他韦-伏西瑞韦治疗12至17岁青少年HCV感染
这项2期多中心开放标签研究评估了索磷布韦-维帕他韦-伏西瑞韦(400/100/100 mg每日一次)在12至17岁慢性HCV感染青少年中的安全性、疗效和药代动力学,21例患者中DAA初治者治疗8周,肝硬化或既往DAA失败者治疗12周,全部21例(100%)达到SVR12,最常见不良事件为腹痛和头痛(各24%)及恶心(19%),无不良事件导致停药。
要点
- 21例12至17岁慢性HCV青少年中,100%(21/21)达到SVR12。
- 最常见不良事件为腹痛和头痛(各24%)及恶心(19%),无因不良事件停药。
- 唯一严重不良事件为低血压,被认为与研究药物相关,当天缓解且未中断治疗。
核心结论
- 索磷布韦-维帕他韦-伏西瑞韦泛基因型方案在治疗青少年慢性HCV感染中高效且耐受性良好。
研究设计与样本
- 这项2期多中心开放标签研究纳入21例12至17岁慢性HCV感染青少年,所有患者均未接受过HCV DAA治疗且无肝硬化。
- DAA初治者接受索磷布韦-维帕他韦-伏西瑞韦400/100/100 mg每日一次治疗8周,肝硬化或既往DAA失败者治疗12周。
- 主要疗效终点为治疗结束后12周持续病毒学应答(SVR12)。
- 对14例患者在治疗第2周或第4周进行密集药代动力学采样,所有患者均采集群体药代动力学样本。
主要发现
- 所有患者(n=21)均未接受过HCV DAA治疗且无肝硬化,HCV基因3a型感染最常见,占43%。
- 总体100%的患者(21/21)达到SVR12。
- 最常见不良事件为腹痛和头痛(各24%)及恶心(19%),无不良事件导致停药。
- 唯一严重不良事件为低血压,被认为与研究药物相关,当天缓解且未中断治疗。
- 索磷布韦-维帕他韦-伏西瑞韦暴露量与成人中观察到的相似。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Sofosbuvir-velpatasvir-voxilaprevir is a pangenotypic regimen for chronic HCV infection. In the USA and Europe, sofosbuvir-velpatasvir-voxilaprevir once daily for 12 weeks is indicated for adults who previously received an HCV NS5A inhibitor. In Europe, sofosbuvir-velpatasvir-voxilaprevir is also indicated in the absence of prior HCV direct-acting antiviral (DAA) therapy as an 8-week or 12-week regimen. In an open-label study, we evaluated the safety, efficacy, and pharmacokinetics of sofosbuvir-velpatasvir-voxilaprevir in adolescents 12 to 17 years with chronic HCV of any genotype. METHODS: In this Phase 2, multicenter study, sofosbuvir-velpatasvir-voxilaprevir 400/100/100 mg daily was administered to adolescents for 8 weeks if DAA-naïve or for 12 weeks for cirrhosis or prior DAA failure. The key efficacy endpoint was sustained virologic response 12 weeks after therapy (SVR12). Intensive pharmacokinetic sampling was done in 14 patients at week 2 or 4, and samples for population pharmacokinetics were collected in all patients. RESULTS: All patients (n = 21) were naïve to HCV DAAs, and none had cirrhosis. HCV genotype 3a infection was most common, occurring in 43% of patients. Overall, 100% of patients (21 of 21) reached SVR12. The most common adverse events were abdominal pain and headache (24% each) and nausea (19%); no adverse events led to discontinuation. The only serious adverse event, hypotension, was considered related to study drug and resolved the same day without interruption of treatment. Sofosbuvir-velpatasvir-voxilaprevir exposures were similar to those observed in adults. CONCLUSIONS: The pangenotypic regimen of sofosbuvir-velpatasvir-voxilaprevir is highly efficacious and well-tolerated in treating chronic HCV infection in adolescents.
引用
- Indolfi G, Kelly D, Nebbia G, et al. Sofosbuvir-velpatasvir-voxilaprevir in adolescents 12 to 17 years old with HCV infection. Hepatology. 2022. PMID: 35112372. doi:10.1002/hep.32393
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。